Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D30 versus RENESE R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D30 versus RENESE R.
ALDORIL D30 vs RENESE-R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination